Jan 10, 2022 / 09:30PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome everybody to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcolm Kuno] and Caleb Smith from the team. Our next presenting company is AlloVir. And presenting on behalf of the company, we have CEO Diana Brainard.
I want to remind everybody that there is an Ask a Question feature in the portal. If you would like me to ask a question on your behalf, please feel free to put it in the portal, and I will do so.
And with that, Diana, you can take it away.
Diana M. Brainard - AlloVir, Inc. - CEO & Director
Great. Thanks so much, Anupam. Great. Well, I'm delighted to be here as CEO of AlloVir and thrilled to share an update on the incredible progress we've made over the last year, advancing our pipeline of allogeneic off-the-shelf viral-specific T cells.
So I want to start on Slide 3 by walking through a few key numbers that help summarize who
Allovir Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers